Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.
CagriSema significantly enhances weight loss compared to semaglutide, cagrilintide, and placebo, with a favorable safety profile, but long-term effects need further study.
Where it sits
this study against the rest of the cagrilintide (am833) corpusSummary and findings
The study systematically reviewed and meta-analyzed seven RCTs involving 8,069 overweight or obese individuals to assess the efficacy and safety of CagriSema, a combination of cagrilintide and semaglutide. CagriSema significantly reduced weight compared to semaglutide, cagrilintide, and placebo. Adverse events were mainly gastrointestinal and injection-site reactions.
Abstract
To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals. A systematic review and meta-analysis was conducted in accordance with PRISMA and Cochrane guidelines. Seven randomized controlled trials (RCTs) (n = 8,069) were included. Pooled analyses were performed using random-effects models, including subgrouping based on type 2 diabetes status. Risk of bias was assessed with RoB 2, and certainty of evidence was graded with GRADE. CagriSema produced significantly greater weight loss than semaglutide (MD = -7.58 kg; 95% CI = -10.30 to -4.86; p < 0.00001), cagrilintide (MD -9.24 kg; 95% CI -10.46 to -8.02, p < 0.00001), and placebo (MD = -13.99 kg; 95% CI = -18.38 to -9.61; p < 0.00001). Glycemic outcomes were heterogeneous, but lipid parameters improved versus placebo. Adverse events were primarily gastrointestinal and injection-site reactions, with no increase in serious adverse events. CagriSema provides substantial and clinically meaningful weight reduction with a favorable safety profile. Importantly, it demonstrates superior efficacy to both cagrilintide and semaglutide, highlighting its therapeutic potential. Future large-scale trials are required to confirm long-term safety and durability, especially given its clear advantage over semaglutide in reducing body weight.
Background
The study addresses the need for effective weight loss interventions in overweight or obese individuals, particularly those with type 2 diabetes. Previous research has shown that both cagrilintide and semaglutide can aid in weight reduction, but their combination as CagriSema had not been thoroughly evaluated. This study aims to fill that gap by assessing the efficacy and safety of CagriSema compared to its individual components and placebo.
Methods
The research conducted a systematic review and meta-analysis of seven randomized controlled trials involving 8,069 participants. The trials compared the effects of CagriSema, a fixed-dose combination of cagrilintide and semaglutide, against placebo, cagrilintide, and semaglutide monotherapy. The primary outcome was weight loss, analyzed using random-effects models, with subgroup analyses based on type 2 diabetes status. Risk of bias was evaluated using RoB 2, and the certainty of evidence was graded with GRADE.
Results
CagriSema resulted in significantly greater weight loss compared to semaglutide (MD = -7.58 kg; 95% CI = -10.30 to -4.86; p < 0.00001), cagrilintide (MD = -9.24 kg; 95% CI = -10.46 to -8.02; p < 0.00001), and placebo (MD = -13.99 kg; 95% CI = -18.38 to -9.61; p < 0.00001). Glycemic outcomes were variable, but lipid parameters improved compared to placebo. Adverse events were mostly gastrointestinal and injection-site reactions, with no significant increase in serious adverse events.
Interpretation
The findings suggest that CagriSema offers a clinically meaningful advantage in weight reduction over its individual components and placebo. However, the clinical significance of the glycemic and lipid outcomes remains less clear due to heterogeneity. The study's reliance on pooled data introduces potential variability, and further large-scale trials are necessary to confirm long-term safety and efficacy. The results align with existing literature on the efficacy of GLP-1 receptor agonists and amylin analogues but highlight the potential of their combination.
Key findings
- MD = -7.58 kg vs semaglutide; 95% CI = -10.30 to -4.86; p < 0.00001
- MD = -9.24 kg vs cagrilintide; 95% CI = -10.46 to -8.02; p < 0.00001
- MD = -13.99 kg vs placebo; 95% CI = -18.38 to -9.61; p < 0.00001
- n = 8,069 across seven RCTs
- Adverse events primarily gastrointestinal and injection-site reactions
Limitations
- Pooled data from multiple RCTs
- Heterogeneity in glycemic outcomes
- Long-term safety not confirmed
- Potential variability due to random-effects model